Supplementary Table S6 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Authors: Kai Yu, Rebecca S. Tidwell, Tharakeswara K. Bathala et al.
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Abstract

<jats:p>&lt;p&gt;Operating characteristics under varying objective response and disease control rates.&lt;/p&gt;</jats:p>

Keywords

poperating characteristics varying objective response

Related Articles

Anticipating the risks of CEAS reform: looking to the United States from Germany

Steffi Colao - Unknown

Read More
Supplementary Table S10 from Clinical Validation of Tissue and Liquid Companion Diagnostics for &lt;i&gt;BRAF&lt;/i&gt; V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study

Gregory J. Riely, Jean-François Martini et al. - Unknown

Read More
Supplementary Figure S7 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Tidwell et al. - Unknown

Read More
Tiny crystals from a 17th-century shipwreck hold secrets of a global supply chain at the dawn of capitalism

Anthony Clarke, Chris Kirkland - Unknown

Read More
Research in the Age of Artificial Intelligence: early learning from our insights pipeline

Reda Sadki - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0